About one third of cancers detected by PSA screening at age 70, and more than half at age 80, are unlikely to become clinically meaningful within 15 years.

The magnitude of the reduction in prostate cancer deaths from population-based PSA screening is too small for a clinical and public health benefit. PSA screening of the general male population ...

Men diagnosed at screening aged 50 years projected to have 16% chance that cancer would not have been detected within 15 years.

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

The understanding of prostate cancer has significantly evolved in the past 15 years. Therefore, many people — including primary care providers — may not be aware of the current guidelines for prostate ...

Researchers at Queen Mary University of London have found that the likelihood of prostate cancer overdiagnosis – the ...

Over the past decade, millions of men without symptoms of prostate cancer have voluntarily undergone a prostate-specific ...

Researchers at Queen Mary University of London have found that the likelihood of prostate cancer overdiagnosis – the detection of a cancer that would never have been diagnosed during a patient’s ...

A single round of prostate cancer screening that included a prostate-specific antigen (PSA) test, a kallikrein panel, and an MRI detected one additional high-grade cancer per 196 men and one low-grade ...

The NHS will not be automatically inviting all men above a certain age to check for prostate cancer, unlike the approach for some other cancers. The UK National Screening Committee has suggested that ...

Prostate-cancer screening based on prostate-specific antigen (PSA) levels in the blood was introduced—and readily adopted—in the United States around the late 1980s. But this screening method, in ...